News | Radiation Therapy | September 19, 2017

Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017

Highlights include Halcyon IMRT platform and HyperArc high-definition radiotherapy system

Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017

September 19, 2017 — Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition radiotherapy (HDRT) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 24-27 in San Diego. The company also will host its Users Meeting on Sept. 23 prior to the ASTRO meeting.

The Halcyon platform helps simplify and enhance virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), while HyperArc HDRT is an advanced type of radiosurgery treatment.

In addition to Halcyon and HyperArc, Varian will showcase these solutions for simplifying and increasing access to advanced cancer care:

  • Eclipse 15.5 featuring treatment planning for HyperArc HDRT, RapidPlan knowledge-based planning, multicriteria optimization (MCO), plus fast optimization and dose calculation;
  • Iterative cone beam computed tomography (CBCT) on the TrueBeam platform, which produces exceptionally high quality images, according to the company, for better visualization of soft tissue structures;
  • ProBeam proton therapy, configurable as single- or multi-room solutions featuring gantries that rotate a full 360 degrees, RapidScan high-speed pencil-beam scanning for single-breath-hold lung SBPT and iterative CBCT for enhanced soft tissue resolution; and
  • Varian Marketplace, a digital marketplace for Varian and customer apps and software product extensions to solve real-world clinical and operational problems.

The Varian Users Meeting will provide attendees with new insights on the latest Varian technology. Topics include:

  • Early experience with the Halcyon system;
  • Multicriteria optimization and high-performance computing;
  • Using 360 Oncology care management to make multidisciplinary tumor boards smarter and more efficient;
  • Robust planning for proton therapy using the Eclipse system;
  • Multi-modality imaging in treatment planning, delivery and response assessment; and
  • First clinical impressions of HyperArc for treating brain metastases.

For more information: www.varian.com

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...